A veteran comes to your clinic having not slept a full night in months. Not because he can’t fall asleep, but because every time he does, the same firefight plays out behind his eyes and he wakes up soaked in sweat with his heart pounding. He’s already on an SSRI. It steadied his mood and took the edge off his daytime anxiety, but the nightmares kept coming. So you reach for a drug that started its life lowering blood pressure: prazosin. And here’s where it gets interesting, because whether that prescription helps may be one of the most genuinely contested questions in PTSD pharmacology right now.
Prazosin is a topic that rewards a student who understands mechanism, knows the data, and can hold two contradictory trials in their head without panicking. It shows up on boards. It shows up in the VA clinics where a huge share of PMHNPs will eventually work. And it teaches you something bigger than one drug: how to prescribe responsibly when the evidence refuses to give you a clean answer.
A blood pressure pill that wandered into psychiatry
Prazosin is an alpha-1 adrenergic antagonist. That’s the whole pharmacological story in one phrase, and it’s worth slowing down on because the mechanism is the part boards love. Alpha-1 receptors sit on blood vessels, and blocking them relaxes those vessels and drops blood pressure, which is why prazosin was first marketed decades ago as an antihypertensive. The same receptors also sit in the central nervous system, where they respond to norepinephrine.
PTSD, at the level of brain chemistry, looks a lot like a disorder of too much noradrenergic activity, especially at night. During trauma-related nightmares, central norepinephrine surges. Prazosin crosses into the brain and blocks the alpha-1 receptors that norepinephrine would otherwise activate, turning down that adrenergic storm during sleep. The result, at least in theory, is fewer nightmares and less of the 3 a.m. wide-awake terror. This is why prazosin works on the sleep and nightmare piece of PTSD specifically, and not the disorder as a whole. It’s a targeted tool, and knowing exactly what it targets is half of using it well.
One distinction trips up students constantly, so lock it in now. Prazosin is an alpha-1 antagonist. Clonidine, which also gets used for PTSD-related arousal, is an alpha-2 agonist. Different receptor, opposite verb, both lowering noradrenergic tone by different routes. Boards adore that kind of side-by-side, and mixing them up is an easy way to lose a question you actually understood.

The evidence that built prazosin’s reputation
The prazosin story is really the story of one researcher, Murray Raskind, and a run of studies out of the Seattle VA. His placebo-controlled trial published in The American Journal of Psychiatry back in 2003, “Reduction of Nightmares and Other PTSD Symptoms in Combat Veterans by Prazosin,” showed combat veterans getting meaningful relief from trauma nightmares and disturbed sleep. A decade later, Raskind and colleagues followed up in the same journal with a 2013 trial in active-duty soldiers returning from Iraq and Afghanistan, and again prazosin beat placebo on nightmares and sleep quality.
For years that was the picture: a cheap, generic, mechanistically sensible drug with positive randomized data for one of the most miserable symptoms in psychiatry. Prazosin became a go-to. The Carlat Psychiatry Report, in its practical teaching on PTSD, has long walked clinicians through exactly this reasoning, framing prazosin as the tool you reach for when the nightmares are the problem and the SSRI isn’t touching them.
Then came the trial that complicated everything.
The study that split the field
In 2018, a large multisite trial run through the VA Cooperative Studies Program, again with Raskind himself involved, tested prazosin in more than 300 veterans with chronic PTSD. This was the rigorous, well-powered study the field had been waiting for. Prazosin did no better than placebo. Not on nightmares, not on sleep, not on overall PTSD severity.
That result landed hard, and it’s exactly the kind of thing you need to be ready to talk about. How does a drug with two prior positive trials suddenly flatline in the biggest study of all? A few explanations matter for your understanding. The veterans in the 2018 trial had chronic, long-standing PTSD and were clinically stable, which may have left less room to show improvement. There’s also a real possibility, raised by the researchers themselves, that prazosin works for a subgroup rather than everyone who reports nightmares. Not every patient who says “I have nightmares” has the hyperadrenergic biology prazosin is designed to quiet. Some nightmares are driven by other things entirely, and prazosin can’t touch those.
So the honest summary is messy. We have positive trials and a big negative one, and reasonable experts read that mixed record in different directions. That’s not a failure of the science. That’s what real medicine often looks like before the picture fully resolves.
Why prazosin is still on the table
Here’s what surprises students: despite that negative trial, prazosin didn’t disappear. The VA and Department of Defense clinical practice guideline still recognizes it for PTSD-associated nightmares and sleep disturbance, and it remains a common, defensible choice in practice. The 2024–2025 update to the PTSD psychopharmacology algorithm, published in the literature as a guide for prescribers, continues to give prazosin a defined role for the sleep and nightmare component of PTSD rather than tossing it out over a single negative study.
The reasoning behind keeping it is sound. The two FDA-approved medications for PTSD are both SSRIs, sertraline and paroxetine, and neither does much for trauma nightmares specifically. That leaves a real gap, and prazosin is cheap, generic, non-addictive, and supported by years of clinical experience and some positive data. When a patient is being tormented by nightmares and the alternatives are limited, a careful trial of prazosin with honest expectations is a reasonable thing to offer. The drug also seems to help certain subgroups, including some patients with comorbid alcohol use disorder, which keeps it relevant in exactly the populations many PMHNPs serve.

How to actually start it without hurting someone
This is where prazosin becomes a hands-on skill, and it’s the part most likely to bite a new prescriber. Remember what this drug originally did: it drops blood pressure. The single most important safety concept is the first-dose phenomenon. Give a naive patient too much prazosin too fast and they can have orthostatic hypotension severe enough to cause dizziness or even syncope when they stand up, which for an older patient stumbling to the bathroom at night is a fall and a fractured hip waiting to happen.
So you start low and you go slow. The standard approach is 1 mg at bedtime to begin, deliberately small, given at night when the patient is already lying down. From there you titrate up in 1 to 2 mg steps every several days, watching blood pressure and asking specifically about lightheadedness on standing. Effective doses vary widely. The Raskind protocols pushed substantially higher than people expect, landing on average around 16 mg in men and roughly 7 mg in women, a real sex difference worth remembering, with dosing commonly going up toward 15 to 20 mg at bedtime in veterans. Plenty of civilian patients respond at much lower doses, in the single-digit milligram range. The number that matters is the one that controls the nightmares without dropping the patient’s pressure out from under them, and you find it by titrating to effect.
Counsel the patient before they take the first dose. Tell them to take it at bedtime, to stand up slowly, and to expect that the dizziness, if it comes, usually settles as their body adjusts over the first days to weeks. That five-minute conversation is the difference between a patient who sticks with treatment and one who takes a single dose, feels awful, and quits.
Why this belongs in your core knowledge
If you’re studying for boards, prazosin is high-yield in a way that goes beyond memorizing a dose. A question can come at you from several angles at once. It can test the mechanism and ask you to pick “alpha-1 antagonist” out of a lineup that includes alpha-2 agonists and beta blockers. It can test the indication and ask which symptom of PTSD prazosin targets, where “nightmares and sleep disturbance” is the answer and “core re-experiencing during the day” is the trap. It can test safety and ask why you start at 1 mg at night, where orthostatic hypotension and the first-dose effect are the point. Understand the drug as a story and all of those collapse into one piece of knowledge instead of four flashcards.
The deeper lesson is the one that will outlast any exam. Prazosin is a case study in prescribing under uncertainty. You will spend your whole career with patients whose situations don’t match a clean trial result, and prazosin teaches you how to hold that tension professionally: you know the positive studies, you know the negative one, you know the guideline still supports a trial, and you make a shared decision with a suffering patient instead of pretending the data is cleaner than it is. The clinician who can say “the evidence here is genuinely mixed, here’s what we know, and here’s what I’d suggest we try” is the one patients trust and the one colleagues respect.
That’s also what separates a prescriber from a pill dispenser. Anyone can write for sertraline. Knowing when to add prazosin, how to start it safely, what to tell the patient, how to set expectations honestly, and when the nightmares aren’t responding and it’s time to reassess, that’s clinical judgment. That’s the PMHNP you’re working to become.
So when prazosin shows up on exam day, and in the VA clinic, and in the chart of a veteran who just wants one night of real sleep, I want you to feel ready instead of rattled. You know it’s an alpha-1 antagonist quieting the brain’s norepinephrine. You know the Raskind trials said yes and the big 2018 VA trial said no. You know the guideline still gives it a role for nightmares. You know to start at 1 mg at bedtime and titrate up while you watch for orthostasis. That’s not trivia. That’s the kind of grounded, honest competence that makes you safe.
Keep going. Every drug you learn this deeply is one more place you’ll move with confidence while everyone around you is guessing. If you’re ready to turn scattered pharmacology facts into the kind of board-ready, clinically grounded mastery that actually holds up under pressure, come study with us at PMHNPReview.org — where high-yield psychopharmacology meets real clinical reasoning, and where future PMHNPs become the clinician their patients are lucky to have.
